Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries

Summary

Following replacement therapy with coagulation factor VIII (FVIII), up to 30 % of haemophilia A patients develop FVIII-specific inhibitory antibodies (FVIII inhibitors). Immune tolerance induction (ITI) is not always successful, resulting in a need for alternative treatments for FVIII inhibitor-positive patients. As tolerance induction in the course of ITI appears to involve the formation of anti-idiotypes specific for anti-FVIII antibodies, such anti-idiotypes might be used to restore haemostasis in haemophilia A patients with FVIII inhibitors. We isolated antiidiotypic antibody fragments (scFvs) binding to murine FVIII inhibitors 2-76 and 2-77 from phage-displayed libraries. FVIII inhibitor/anti-idiotype interactions were very specific as no cross-reactivity with other FVIII inhibitors or isotype controls was observed. ScFvs blocked binding of FVIII inhibitors to FVIII and neutralised their cognate inhibitors in vitro and a monoclonal mouse model. In addition, scFv JkH5 specific for FVIII inhibitor 2-76 stained 2-76-producing hybridoma cells. JkH5 residues R52 and Y226, located in complementary determining regions, were identified as crucial for the JkH5/2-76 interaction using JkH5 alanine mutants. SPR spectroscopy revealed that JkH5 interacts with FVIII inhibitor 2-76 with nanomolar affinity. Thus, FVIII inhibitorspecific, high-affinity anti-idiotypes can be isolated from phagedisplayed libraries and neutralise their respective inhibitors. Furthermore, we show that anti-idiotypic scFvs might be utilised to specifically target inhibitor-specific B cells. Hence, a pool of anti-idiotypes could enable the reestablishment of haemostasis in the presence of FVIII inhibitors in patients or even allow the depletion of inhibitors by targeting inhibitor-specific B cell populations.

Keywords

Haemophilia A - inhibitors - anti-idiotypes - phage display - FVIII

• References

• 1 Iorio A, Halimeh S, Holzhauer S. et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 08: 1256-1265.
• 2 Hay CR, Dimichele DM, Study IIT. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-1344.
• 3 Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125C: 373-389.
• 4 Sultan Y, Kazatchkine MD, Maisonneuve P. et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 02: 765-768.
• 5 Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-1505.
• 6 Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII: C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII: C autoantibodies. Proc Natl Acad Sci USA 1987; 84: 828-831.
• 7 Gilles JG, Desqueper BG, Lenk H. et al. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-1388.
• 8 Gilles JG, Grailly SC, De Maeyer M. et al. In vivo neutralization of a C2 domainspecific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. Blood 2004; 103: 2617-2623.
• 9 Jäger V, Büssow K, Wagner A. et al. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 2013; 13: 52.
• 10 Naumann A, Scherger AK, Neuwirth J. et al. Selection and characterisation of FVIII-specific single chain variable fragments. Hamostaseologie 2013; (33) (Suppl. 01) S39-45.
• 11 Markovitz RC, Healey JF, Parker ET. et al. The diversity of the immune response to the A2 domain of human factor VIII. Blood 2013; 121: 2785-2795.
• 12 Meeks SL, Healey JF, Parker ET. et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
• 13 Kahle J, Orlowski A, Stichel D. et al. Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites. Thromb Haemost 2015; 113: 396-405.
• 14 Glanville J, Zhai W, Berka J. et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 2009; 106: 20216-20221.
• 15 van Regenmortel MH. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit 2014; 27: 627-639.
• 16 Braden BC, Goldman ER, Mariuzza RA. et al. Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Immunol Rev 1998; 163: 45-57.
• 17 Gilles JG. Role of anti-idiotypic antibodies in immune tolerance induction. Haemophilia 2010; 16: 80-83.
• 18 Kessel C, Kreuz W, Klich K. et al. Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies. Chem Med Chem 2009; 04: 1364-1370.
• 19 van Helden PM, Kaijen PH, Mauser-Bunschoten EP. et al. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. Haemophilia 2010; 16: 892-901.
• 20 White GC, Rosendaal F, Aledort LM. et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
• 21 Zakas PM, Vanijcharoenkarn K, Markovitz RC. et al. Expanding the Ortholog Approach for Hemophilia Treatment Complicated by Factor VIII Inhibitors. J Thromb Haemost 2015; 13: 72-81.
• 22 Paschal RD, Meeks SL, Neff AT. Development of factor VIII inhibitors in two patients with moderate haemophilia A. Haemophilia 2013; 19: e55-57.
• 23 von Minckwitz G, Harder S, Hövelmann S. et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005; 07: R617-626.
• 24 Kreitman RJ, Wilson WH, White JD. et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-1636.
• 25 Price PW, Mckinney EC, Wang Y. et al. Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas. J Immunol Methods 2009; 343: 28-41.
• 26 Sinclair NR, Panoskaltsis A. The immunoregulatory apparatus and autoimmunity. Immunol Today 1988; 09: 260-265.
• 27 Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 07: 1446-1456.